Long-term effectiveness and safety of antiepileptic drugs in children and adults

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

AIM: To conduct a retrospective comparative analysis of the efficacy and safety of epilepsy therapy with antiepileptic drugs.

MATERIALS AND METHODS: The analysis of the treatment of 428 patients with epilepsy at the Children’s City Hospital No. 8 in Kazan, receiving antiepileptic drugs.

RESULTS: It was found that valproic acid is more effective in the treatment of idiopathic generalized epilepsies compared to focal epilepsies (p = 0.0006). Valproate and carbamazepine were the most effective in the treatment of focal epilepsy with short- and long-term follow-up. Valproic acid is more effective than topiramate (p = 0.02), oxcarbazepine (p = 0.003), and levetiracetam (p = 0.003) in the treatment of focal epilepsy in short- and long-term follow-up. Carbamazepine is more effective than topiramate (p = 0.01), oxcarbazepine (p = 0.02), and levetiracetam (p = 0.001) in the treatment of focal epilepsy in long-term follow-up. It was revealed that more often they complained about side effects when using carbamazepine (63.2%). Levetiracetam was found to be better tolerated compared to valproate (p = 0.0006) and carbamazepine (p = 0.0006). Topiramate is better tolerated than carbamazepine (p = 0.02) and valproate (p = 0.03). Oxcarbazepine is better tolerated than carbamazepine in women (p = 0.04).

CONCLUSIONS: When choosing an antiepileptic drug, it is necessary to be guided by the principle: first the basic, and then the drugs of the next generations, in the future, rely on information about the tolerability of the drug. It is necessary to evaluate the therapeutic effect of antiepileptic drugs with long-term observation, and use the criterion of “complete absence of seizures” as an indicator of the effectiveness of drugs.

Full Text

Restricted Access

About the authors

Roza M. Shaimardanova

A.Yu. Ratner’s Pediatric City Hospital

Author for correspondence.
Email: roza.shaimardanova@mail.ru
ORCID iD: 0000-0001-6287-8896
SPIN-code: 8819-3304

neurologist

Russian Federation, 11, Galeeva str., Kazan, 420061

Rimma G. Gamirova

Kazan (Volga Region) Federal University; Kazan State Medical Academy — Branch Campus of the Russian Medical Academy of Continuing Professional Education

Email: r-gamirov@mail.ru
ORCID iD: 0000-0002-8582-592X
SPIN-code: 2604-6583

 
 
 
Russian Federation, Kazan; Kazan

References

  1. Jones JK, Tilson HH, Lewis JD. Pharmacoepidemiology: defining the field and its core content. Pharmacoepidemiol Drug Saf. 2012;21(7):677–689. doi: 10.1002/pds.3198
  2. Wise L. Risks and benefits of (pharmaco)epidemiology. Ther Adv Drug Saf. 2011;2(3):95–102. doi: 10.1177/2042098611404920
  3. Yur’ev KL. Noveishie – tret’ego pokoleniya – protivoehpilepticheskie preparaty. Ukrainskii meditsinskii zhurnal. 2012;(4):90. (In Russ.)
  4. Andersen M. Research on drug safety and effectiveness using pharmacoepidemiological databases. J Internal Med. 2014;275(6):548–550. doi: 10.1111/joim.12235
  5. Iyer A, Marson A. Pharmacotherapy of focal epilepsy. Expert Opin Pharmacother. 2014;15(11):1543–1551. doi: 10.1517/14656566.2014.922544
  6. Bruen BK, Ku L, Burke MF, Buntin MB. More than four in five office-based physicians could qualify for federal electronic health record incentives. Health Aff (Millwood). 2011;30(3):472–480. doi: 10.1377/hlthaff.2010.0932
  7. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: Evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47(7):1094–1120. doi: 10.1111/j.1528-1167.2006.00585.x
  8. Nevitt SJ, Sudell M, Weston J, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017;(15):12. doi: 10.1002/14651858.CD011412.pub3
  9. Geng H, Wang C. Efficacy and safety of oxcarbazepine in the treatment of children with epilepsy: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2017;13:685–695. doi: 10.2147/NDT.S130269
  10. Nicolson A, Appleton RE, Chadwick DW, et al. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalized epilepsies. J Neurol Neurosurg Psychiatry. 2004;75:75–79.
  11. Hu Y, Huang Y, Quan F, et al. Comparison of the retention rates between carbamazepine and valproate as an initial monotherapy in Chinese patients with partial seizures: A ten-year follow-up, observational study. Seizure-Eur J Epilep. 2011;20(3):208–213. doi: 10.1016/j.seizure.2010.11.020
  12. Bertsche A, Neininger MP, Dahse AJ, et al. Initial anticonvulsant monotherapy in routine care of children and adolescents: levetiracetam fails more frequently than valproate and oxcarbazepine due to a lack of effectiveness. Eur J Pediatr. 2014;173(1):87–92. doi: 10.1007/s00431-013-2125-1
  13. Zhu F, Lang SY, Wang XQ, et al. Long-term Effectiveness of Antiepileptic Drug Monotherapy in Partial Epileptic Patients: A 7-year Study in an Epilepsy Center in China. Chin Med J (Engl). 2015;128(22):3015–3022. doi: 10.4103/0366-6999.168968
  14. Nevitt SJ, Sudell M, Tudur Smith C, et al. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2019;24:6: CD012065. doi: 10.1002/14651858.CD012065.pub3
  15. Zeng QY, Fan TT, Zhu P, et al. Comparative Long-Term Effectiveness of a Monotherapy with Five Antiepileptic Drugs for Focal Epilepsy in Adult Patients: A Prospective Cohort Study. PLoS One. 2015;6(10):7: e0131566. doi: 10.1371/journal.pone. 0131566.

Copyright (c) 2021 Shaimardanova R.M., Gamirova R.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 65565 от 04.05.2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies